Study Finds DTG+3TC As ART Therapy Regimen For Patients With HIV Successfully Suppress Viral Load

Infectious Disease Advisor (4/25) reported, “Estimated rates of virologic suppression were high, and estimated rates of virologic failure were low among patients with HIV infection in real-world settings who initiated or switched to antiretroviral therapy with dolutegravir plus lamivudine.” Further, outcomes of the 2-drug antiretroviral (ART) therapy regimen of dolutegravir (DTG) plus lamivudine (3TC) in real-world settings “are consistent with those observed in phase 3 clinical trials, confirming its efficacy, tolerability, and high barrier to resistance among diverse populations with HIV infections.” The study findings were published in Infectious Diseases and Therapy.